Del Rosso James Q
Adjunct Clinical Professor (Dermatology), Touro University Nevada, Henderson, Nevada; Research Director, Del Rosso Dermatology Research Center, Las Vegas, Nevada.
J Clin Aesthet Dermatol. 2016 Nov;9(11 Suppl 1):S3-S11.
Ingenol mebutate is available as a topical gel formulation approved for the treatment of actinic keratosis. Two different concentrations are available for treatment of actinic keratoses at specific anatomic sites with the advantages of short durations of therapy and limited "down time" related to visible inflammation as compared to other topical agents. Due to the various modes of action of ingenol mebutate, it has also been used for treatment of disease states other than actinic keratosis. This manuscript discusses the suggested modes of action of ingenol mebutate and reviews publications on the use of ingenol mebutate gel for cutaneous disorders other than actinic keratosis, including squamous cell carcinoma basal cell carcinoma, actinic cheilitis, anogenital warts, and others. Author commentaries are also included with the goal of providing relevant clinical insights.
ingenol mebutate有外用凝胶制剂，已被批准用于治疗光化性角化病。有两种不同浓度的制剂可用于治疗特定解剖部位的光化性角化病，与其他外用药物相比，具有治疗时间短和与可见炎症相关的“停机时间”有限的优点。由于ingenol mebutate的作用方式多样，它也被用于治疗光化性角化病以外的疾病状态。本文讨论了ingenol mebutate的建议作用方式，并综述了关于ingenol mebutate凝胶用于治疗光化性角化病以外的皮肤疾病的文献，包括鳞状细胞癌、基底细胞癌、光化性唇炎、肛门生殖器疣等。还包括作者评论，目的是提供相关的临床见解。
